Esperion to Host Virtual Key Opinion Leader Event on Wednesday, January 22, 2025, at 11:30 a.m. ET.

Group 1 - Esperion will host a virtual key opinion leader (KOL) event to discuss the real-world use of its medications NEXLETOL and NEXLIZET for LDL-Cholesterol management [1] - The event will feature LeAnne Bloedon and Dr. Patrick Moriarty, highlighting the ongoing unmet need in LDL-Cholesterol management to prevent cardiovascular disease [1] - Registration for the KOL webinar is available, and a live audio webcast will be accessible on Esperion's website [1] Group 2 - Esperion Therapeutics is a commercial stage biopharmaceutical company focused on developing new medicines for patients at risk of cardiovascular disease with elevated LDL-C [2] - The company has developed the only FDA-approved oral, once-daily, non-statin medications for this patient group, supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial [2] - Esperion is advancing its next-generation program focused on ATP citrate lyase inhibitors (ACLYi), enabling rational drug design for potent and specific inhibitors [2] Group 3 - Esperion is evolving into a leading global biopharmaceutical company through commercial execution, international partnerships, and advancements in its pre-clinical pipeline [3]